# Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

> **NCT02217839** · PHASE1 · COMPLETED · sponsor: **Aspireo Pharmaceuticals Limited** · enrollment: 42 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DG3173
- **DRUG:** DG3173+Octreotide
- **DRUG:** Octreotide
- **DRUG:** DG3173 Placebo
- **DRUG:** DG3173 Placebo+Octreotide Placebo
- **DRUG:** Octreotide+DG3173 Placebo

## Key facts

- **NCT ID:** NCT02217839
- **Lead sponsor:** Aspireo Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-01
- **Final completion:** —
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02217839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02217839, "Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT02217839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*